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Objective: According to experimental ﬁndings, oxycodone (OX)
could have some advantages over morphine (MO) in clinical
models of visceral pain. It was hypothesized that OX could have
some advantages over MO in terms of eﬃcacy and dose escalation
in pancreatic cancer pain.
Methods: Sixty patients with pancreatic cancer with a pain intensity
rating of 4/10 who required opioids were included in the study.
Patients were randomized to receive 30mg/d of sustained release
oral MO or sustained release oral OX (20mg/d). Opioid doses were
increased according to the clinical needs. Daily doses of opioids,
pain and symptom intensity were recorded at admission (T0) and at
weekly intervals for the subsequent 4 weeks (T1, T2, T3, and T4),
with an extension at 8 weeks (T8). Opioid escalation index (OEI) as
percentage (OEI %) and in mg (OEI mg) was calculated.
Results: Nineteen and 20 patients in groups OX and MO,
respectively, were followed for the entire period of study (T4).
No diﬀerences between groups were found in age (P=0.400),
Karnofsky (P=0.667), or escalation indexes at T4 and T8 (OEImg,
P=0.945 and OEI %, P=0.295). No statistical diﬀerences in pain
and symptoms intensity between the groups were observed.
Conclusion: OX and MO provided similar analgesia and adverse
eﬀects with similar escalating doses in patients with pancreatic
cancer pain, resembling observations reported in the general cancer
pain population. The experimental hypothesis that OX would be
superior to MO in the clinical model of pancreatic cancer pain was
not conﬁrmed.
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Oral morphine (MO) has been widely used for treatingcancer pain of moderate-to-severe intensity, and
remains the opioid of choice for its familiarity, availability,
and costs rather than proven superiority.1 Oxycodone (OX)
has been used clinically for the same indications and has
been found to provide analgesia comparable with that of
MO and mediated primarily in the central nervous system.2
However, experimental observations suggest that OX and
MO produce antinociception through distinctly diﬀerent
opioid receptor populations and OX seems to act as
k-agonist with a relatively low aﬃnity for m-opioid recep-
tors.3 The k-agonists exert analgesic activity in a wide
variety of visceral pain models. These eﬀects are mediated
at peripherally located k-receptors and possibly through
additional nonopioid action at sodium channels located on
peripheral nerve endings. Their analgesic potency seems to
be enhanced in the presence of local inﬂammation.4 The
proﬁle of k-agonists in visceral pain models suggests that
opioids with these characteristics might be useful to treat
a variety of visceral pain conditions.
Although MO and OX have been used for years,
directly comparing their pharmacology and eﬀects has been
studied more intensively over the last decade. Controversies
exist about the intrinsic antinociceptive eﬀects of OX.3,5–11
Experimental and human studies suggest that these eﬀects
are distinctly diﬀerent from those mediating eﬀects of
MO,3,5,6 which could explain the asymmetric tolerance with
MO.7 In a multimodal, tissue-diﬀerentiated experimental
pain models in humans, OX showed a superior analgesic
eﬀect to MO in visceral pain, but a similar analgesia in pain
modulation of the skin and muscles.8 This diﬀerentiated
eﬀect has been attributed to the peripheral k-agonist
activity of OX.6 OX plasma concentration correlated better
with the course of the analgesia with no delay in the visceral
pain measures, in comparison with MO.9 However, other
experiments have shown that the eﬀects of OX are likely
mediated through m-opioid receptors.10 More recently, OX
has been reported to exhibit a generalized eﬀect, elevating
threshold for diﬀerent kinds of stimulation, including
cutaneous, deep somatic, and visceral pain stimulation.11
A cancer pain syndrome with an important visceral
component, because of a prevalent local spread, at least
initially, is associated with pancreatic cancer. A neurolytic
celiac plexus block has been advocated to treat the visceral
component in advanced cancer patients.12 Given these
experimental ﬁndings and the potential properties of OX,
we hypothesized that OX could have some advantages over
MO in terms of eﬃcacy and dose escalation in pancreatic
cancer pain.
PATIENTS AND METHODS
Sixty patients with pancreatic cancer who required
opioids were included in the study. Inclusion criteria were
pancreatic cancer with a local disease, presenting abdom-
inal pain with an intensity of 4/10 or more in a numerical
rating scale of 0 to 10, and no longer responsive to
nonopioid analgesics. Exclusion criteria were distant and
bone metastases, or prevalent somatic pain because of
evident peritoneal involvement, changes in chemotherapyCopyright r 2010 by Lippincott Williams & Wilkins
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regimen, radiotherapy, hepatic or renal failure, cognitive
failure, lack of cooperation, extreme ages (below 18 and
above 80 y), and a Karnofsky status less than 50. Informed
consent and institutional approval were obtained.
Patients were randomized by a computer system in
2 groups. Patients in group MO started with 30mg/d of
sustained release oral MO, whereas patients in group OX
received equivalent MO doses of sustained release oral OX
(20mg/d), according to an approximate MO-OX ratio of
1.5:1.13,14
For patients who required an increase in the dose
because of increasing pain (more than 4/10, or more than
3 breakthrough pain medications per day) during the period
of study, opioid doses were increased according to the
clinical needs. In both groups, oral MO in doses of 1/6 of
the daily dose was provided as a rescue dose for episodes of
breakthrough pain (5mg of oral MO, initially).
Patients were recruited and followed during admission
to the palliative care unit, as outpatients and at home.
Physicians provided frequent call contacts to adjust the
opioid dose at any time and to reproduce a realistic clinical-
care scenario. Adjuvants and symptomatic drugs were
prescribed as indicated by the clinical situation. The
following parameters were collected as reported by patients:
average pain intensity in the last 24 hours (numerical rating
scale 0 to 10), opioid-related symptoms, including nausea
and vomiting, drowsiness, and confusion, by using a scale
from 0 to 3 (absent, slight, moderate, and severe). For
constipation the scale was: 0=one passage/1 to 2 days,
1=one passage/3 to 4 days, 2=one passage/more than 4
days, and 3=only by enema. Daily doses of opioids, pain
and symptom intensity were recorded at admission (T0)
and at weekly intervals for the subsequent 4 weeks (T1, T2,
T3, and T4), with an extension at 8 weeks (T8). Opioid
escalation index (OEI) as percentage (OEI %) was
calculated according to the following formula: OEI %:
[(x-y)/1]/d100, where x is dose at the end of study and y is
the dose at admission. OEI mg was calculated with the
following formula: (x-y)/d.15 The number of patients who
needed an opioid switching, because of an inconvenient
balance between analgesia and adverse eﬀects, or unavail-
ability of oral route, were recorded.
Statistics
The primary objective of the study was to evaluate
pain intensity scores at diﬀerent time intervals. A power
analysis indicate that a sample size of 25 patients per group
would allow the detection of a 20% diﬀerence in pain
intensity score (P<0.05, power=0.8). This computation
assumes that the mean diﬀerence is 0.20 with a 95%
conﬁdence interval of 0.07-0.33 and the common within-
group SD of 0.28. Frequency analysis was performed with
w2 test. The univariate repeated measures analysis of
variance and the paired Wilcoxon signed rank test were
used to compare the means or the scores of parametric or
nonparametric variables, respectively, at the diﬀerent time
intervals. The 1-way analysis of variance and Mann-
Whitney U statistic test was used to compare the diﬀerent
parametric or nonparametric variables. All P values were
2-sided and values less than 0.05 were considered statisti-
cally signiﬁcant.
RESULTS
Forty-six patients of 60 randomized patients com-
pleted baseline evaluation (T0), 21 patients in group OX
and 25 in group MO. The remaining 14 patients did not
complete baseline evaluation because they were lost to
follow-up. Of the forty-six patients, 27 patients were
females, the mean age was 63.2 years (SD 9.48), and the
mean Karnofsky status was 70 (SD 11.8).
Nineteen and 20 patients in group OX and MO,
respectively, completed 4 weeks of follow-up (T4). In group
OX, 1 patient died before T2, two patients were switched
to transdermal fentanyl, and 3 patients were switched to
intravenous MO for bowel obstruction. Eight patients died
before T8 (see ﬂow diagram in Table 1, and the number of
patients evaluated at the diﬀerent intervals in Table 2).
In group MO, 1 patient was switched to transdermal
buprenorphine for bowel obstruction and died before T1,
one patient died before T3, three patients were switched to
intravenous MO for bowel obstruction, and 2 patients were
switched to intravenous MO between T4 and T8. Eight
patients died before T8 (see ﬂow diagram in Table 1, and
the number of patients evaluated at the diﬀerent intervals in
Table 2). The number of patients who died before T8 was
similar in the 2 groups, and patients who were switched to
other opioids.
No diﬀerences were found between groups in age
(P=0.400), Karnofsky (P=0.667), and escalation indexes
(OEI mg, P=0.945 and OEI %, P=0.295), when compar-
ing T4 to T8. Data on pain and symptom intensity, opioid
doses, and OEI of OX and MO are reported in Table 2. No
statistical diﬀerences were observed. The number of rescue
doses was small and similar between the 2 groups. No
diﬀerences in the number of patients receiving adjuvant or
symptomatic drugs were found between the 2 groups.
DISCUSSION
Recent investigations have shown that opioids may
have distinct proﬁles under various experimental conditions.
TABLE 1. Flow Diagram of Randomized Patients
30 Patients Randomized on Oxycodone 30 Patients Randomized on Morphine
46 patients with a baseline evaluation at T0
21 patients T0 25 patients
9 patients lost in follow-up 5 patients lost in follow-up
1 patient died 1 patient switched and died
1 patient switched 1 patient died
3 patients switched
19 patients completed T4 20 patients completed
4 patients switched 2 patients switched
8 patients died 8 patients died
7 patients T8 10 patients
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Speciﬁcally marked diﬀerences in the antinociceptive proﬁles
of OX and MO have been found in some experimental and
clinical models, including chronic pancreatitis and thermal
pain threshold in the esophagus, suggesting signiﬁcant
between-opioid diﬀerences in opioid receptor signaling.6,16
The k-opioid receptor agonists are particularly eﬀective
analgesics in experimental models of visceral pain, acting
peripherally.4,17,18 It has been shown that OX may be
superior to MO in the treatment of visceral pain,6,8 possibly
because of the prevalent peripheral activity of OX as a
putative k-agonist,3 and a relatively low aﬃnity for m-
receptors.19,20 We selected patients with pancreatic pain as a
model of clinical visceral pain for its tendency to maintain a
local spread, although pain mechanism may change in time
because of the progression of disease.21 According to these
observations, it was expected that OX would have oﬀer some
advantages over MO in terms of analgesia and opioid doses,
because of its k-agonist activity with preferential localization
in visceral tissues.
This study showed no diﬀerences between OX and
MO started at equivalent doses in patients with pain
associated with pancreatic cancer. Pain intensity similarly
decreased in both groups and the trend in symptom
intensity was similar, as well as the use of breakthrough
pain medication. MO was used in both groups as no
immediate release preparation of OX was available, unless
in combination.
In group OX, it was noted a tendency to an increase
in intensity of nausea after 2 weeks, and confusion after
8 weeks, although diﬀerences did not attain statistical
signiﬁcance in comparison with group MO at the diﬀerent
intervals examined. Considering the concomitant abdom-
inal disease and treatments received, and possibly the low
number of patients, it is unlikely to draw conclusion about
the responsibility of an opioid as a causal factor in this
context.
The ﬁndings of this study could be attributed to
diﬀerent factors. First, experimental conditions are often
diﬀerent from a clinical scenario and experimental ﬁndings
can not always be translated in daily practice.21 In cancer
patients, multiple mechanisms play a role, including, for
example, the inﬂammatory factors or apparent sprounting
and then destruction of sensory and sympathetic ﬁbers that
innervate the pancreas, which are able to mask pain in the
TABLE 2. Pain, Symptom Intensity, and Opioid Doses in Groups Treated With OX and MO Before Starting Opioids (T0), at Weekly
Intervals (T1, T2, T3, and T4), and After 8 Weeks
T0 T1 T2 T3 T4 T8
No. patients
OX 21 21 20 19 19 7
MO 25 24 24 23 20 10
Pain
OX 7.19 (0.9) 2.09 (2.07)* 1.8 (1.76)* 2.79 (2.04)* 3.15 (3.0)* 2.0 (1.2)*
MO 7.24 (0.66) 1.41 (1.81)* 1.62 (2.04)* 2.17 (2.14)* 2.35 (2.36)* 1.2 (1.03)*
P 0.896 0.232 0.528 0.297 0.492 0.189
Nausea
OX 0.24 (0.43) 0.38 (0.50) 0.50 (0.60)* 0.58 (0.77)* 0.84 (0.90)* 0.85 (0.70)*
MO 0.48 (0.65) 0.54 (0.78) 0.54 (0.66) 0.56 (0.66) 0.60 (0.75) 0.40 (0.70)
P 0.201 0.700 0.883 0.910 0.400 0.143
Drowsiness
OX 0.20 (0.41) 0.45 (0.60) 0.47 (0.61) 0.37 (0.60) 0.37 (0.60) 0.28 (0.50)
MO 0.36 (0.60) 0.83 (0.76)* 0.58 (0.58) 0.43 (0.60) 0.35 (0.59) 0.50 (0.70)
P 0.342 0.086 0.489 0.652 0.917 0.561
Confusion
OX 0.15 (0.37) 0.25 (0.55) 0.26 (0.56) 0.16 (0.37) 0.37 (0.49)* 0.71 (0.49)*
MO 0.16 (0.37) 0.29 (0.55) 0.25 (0.44) 0.26 (0.45) 0.25 (0.44) 0.10 (0.31)
P 0.928 0.722 0.842 0.424 0.429 0.011*
Dry mouth
OX 0.15 (0.36) 0.45 (0.60)* 0.31 (0.47) 0.36 (0.59)* 0.63 (0.68)* 0.71 (0.48)*
MO 0.32 (0.55) 0.75 (0.60)* 0.62 (0.64)* 0.65 (0.64)* 0.60 (0.68)* 1.10 (0.87)*
P 0.282 0.091 0.108 0.122 0.876 0.318
Constipation
OX 0.40 (0.60) 0.55 (0.68) 0.36 (0.49) 0.36 (0.49) 0.63 (0.68) 0.57 (0.53)
MO 0.72 (0.79) 0.79 (0.88) 0.75 (1.11) 0.87 (1.05) 0.70 (0.92) 0.80 (0.91)
P 0.171 0.401 0.261 0.108 0.926 0.741
Opioid doses
OX 20 23.8 (7) 25.5 (8) 27.9 (9) 33.1 (14)*,**,*** 45.7 (24)*,**,***,w
MO 30 35.0 (9)* 36.2 (14)* 41.0 (19)*,** 42.6 (21)*,** 60.0 (46)*,**
OXEI mg 0.44 (0.47) 0.30 (0.33)
OXEI % 2.19 (2.33) 1.50 (1.64)
MOEI mg 0.42 (0.70) 0.29 (0.52)
MOEI % 1.40 (2.34) 0.97 (1.75)





MO indicates morphine; MOEI, opioid escalation index of MO; OX, oxycodone; OXEI, opioid escalation index of OX.
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early stage of disease.22 Secondly, pancreatic pain has been
regarded either as a neuropathic pain condition, because
of the diﬀuse inﬁltration of nerves and celiac plexus, or
somatic pain syndrome, because of the involvement of
peritoneum. As a consequence, the possible advantages
observed in experimental conditions of visceral pain may be
masked by all the factors playing a role in a cancer patient.
Third, OX and its metabolites may still have suﬃcient
m-receptor activity,23 and an aggressive local disease, like
cancer, may impair the expression of peripheral k-opioid
receptors.
Weaknesses of this study include the relatively small size
of the sample. As expected in a population with pancreatic
cancer with a late diagnosis, many patients did not have
complete data for diﬀerent reasons, commonly reported in
advanced cancer population.24 The sample power dropped at
65% at the end of study (4wk), limiting the statistical
validity. The absence of some diﬀerences does not constitute
a claim for equivalence, because of the inevitable number of
dropouts. However, the dropout rates reported in this study
was similar in both groups, consistent with that observed in
earlier comparative studies of opioids13,21 and reﬂects the
diﬃculties in performing controlled trials in this popula-
tion.24 The choice of not blinding the study was directed by
the need to reproduce a daily clinical scenario allowing the
therapeutic ﬂexibility needed to reproduce what happens
in the daily activity. Studies with drugs used for relatively
prolonged periods of time are very diﬃcult to perform,
particularly if patients are then followed up by phone
interviews and visits at the outpatient clinic, and it is diﬃcult
to maintain blinding. Finally, a certain number of patients
developed bowel obstruction, which is typical complication
of pancreatic cancer, and could not continue to take the
study drugs orally.
In conclusion, OX and MO provided similar analgesia
and adverse eﬀects with similar escalating doses in patients
with pancreatic cancer pain, resembling observations re-
ported in the general cancer pain population.2 The experi-
mental hypothesis that OX would be superior to MO in the
clinical model of pancreatic cancer pain was not conﬁrmed.
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